Report cover image

Global Biosimilar Therapeutic Peptides Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 196 Pages
SKU # APRC20356542

Description

Summary

According to APO Research, The global Biosimilar Therapeutic Peptides market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Biosimilar Therapeutic Peptides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Biosimilar Therapeutic Peptides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Biosimilar Therapeutic Peptides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Biosimilar Therapeutic Peptides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Biosimilar Therapeutic Peptides include Takeda Pharmaceuticals, Sanofi, Novartis AG, li Lilly and Company, Pfizer, GlaxoSmithKline, Amgen, AstraZeneca and Teva Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Biosimilar Therapeutic Peptides, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Biosimilar Therapeutic Peptides, also provides the revenue of main regions and countries. Of the upcoming market potential for Biosimilar Therapeutic Peptides, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilar Therapeutic Peptides revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biosimilar Therapeutic Peptides market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Biosimilar Therapeutic Peptides revenue, projected growth trends, production technology, application and end-user industry.

Biosimilar Therapeutic Peptides Segment by Company

Takeda Pharmaceuticals
Sanofi
Novartis AG
li Lilly and Company
Pfizer
GlaxoSmithKline
Amgen
AstraZeneca
Teva Pharmaceuticals
Novo Nordisk
Biosimilar Therapeutic Peptides Segment by Type

Innovative
Generic
Biosimilar Therapeutic Peptides Segment by Application

Cancer
Metabolic Disorders
Dermatology
Gastrointestinal Disorders
Cardiovascular
Central Nervous Systems
Others
Biosimilar Therapeutic Peptides Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Therapeutic Peptides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Therapeutic Peptides and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Therapeutic Peptides.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Biosimilar Therapeutic Peptides in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biosimilar Therapeutic Peptides industry.
Chapter 3: Detailed analysis of Biosimilar Therapeutic Peptides companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilar Therapeutic Peptidesrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Market Analysis by Type
1.2.1 Global Biosimilar Therapeutic Peptides Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Innovative
1.2.3 Generic
1.3 Market Analysis by Application
1.3.1 Global Biosimilar Therapeutic Peptides Market Size Growth Rate by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Metabolic Disorders
1.3.4 Dermatology
1.3.5 Gastrointestinal Disorders
1.3.6 Cardiovascular
1.3.7 Central Nervous Systems
1.3.8 Others
1.4 Global Market Growth Prospects
1.5 Global Biosimilar Therapeutic Peptides Growth Trends by Region
1.5.1 Global Biosimilar Therapeutic Peptides Market Size by Region: 2020 VS 2024 VS 2031
1.5.2 Biosimilar Therapeutic Peptides Market Size by Region (2020-2025)
1.5.3 Biosimilar Therapeutic Peptides Market Size by Region (2026-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
1.8 Years Considered
2 Global Biosimilar Therapeutic Peptides Market Dynamics
2.1 Biosimilar Therapeutic Peptides Industry Trends
2.2 Biosimilar Therapeutic Peptides Industry Drivers
2.3 Biosimilar Therapeutic Peptides Industry Opportunities and Challenges
2.4 Biosimilar Therapeutic Peptides Industry Restraints
3 Competitive Landscape by Company
3.1 Global Biosimilar Therapeutic Peptides Revenue by Company (2020-2025)
3.2 Global Biosimilar Therapeutic Peptides Players Revenue Ranking, 2023 VS 2024 VS 2025
3.3 Global Biosimilar Therapeutic Peptides Key Company Head office and Area Served
3.4 Global Biosimilar Therapeutic Peptides Company, Product Type & Application
3.5 Global Biosimilar Therapeutic Peptides Company Establishment Date
3.6 Market Competitive Analysis
3.6.1 Global Biosimilar Therapeutic Peptides Market CR5 and HHI
3.6.2 Global Top 5 and 10 Biosimilar Therapeutic Peptides Players Market Share by Revenue in 2024
3.6.3 2024 Biosimilar Therapeutic Peptides Tier 1, Tier 2, and Tier 3
4 Biosimilar Therapeutic Peptides Market by Type
4.1 Global Biosimilar Therapeutic Peptides Market Size by Type (2020 VS 2024 VS 2031)
4.2 Global Biosimilar Therapeutic Peptides Market Size by Type (2020-2031)
4.3 Global Biosimilar Therapeutic Peptides Market Size Share by Type (2020-2031)
5 Biosimilar Therapeutic Peptides Market by Application
5.1 Global Biosimilar Therapeutic Peptides Market Size by Application (2020 VS 2024 VS 2031)
5.2 Global Biosimilar Therapeutic Peptides Market Size by Application (2020-2031)
5.3 Global Biosimilar Therapeutic Peptides Market Size Share by Application (2020-2031)
6 Company Profiles
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Comapny Information
6.1.2 Takeda Pharmaceuticals Business Overview
6.1.3 Takeda Pharmaceuticals Biosimilar Therapeutic Peptides Revenue and Gross Margin (US$ Million) & (2020-2025)
6.1.4 Takeda Pharmaceuticals Biosimilar Therapeutic Peptides Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments
6.2 Sanofi
6.2.1 Sanofi Comapny Information
6.2.2 Sanofi Business Overview
6.2.3 Sanofi Biosimilar Therapeutic Peptides Revenue and Gross Margin (US$ Million) & (2020-2025)
6.2.4 Sanofi Biosimilar Therapeutic Peptides Product Portfolio
6.2.5 Sanofi Recent Developments
6.3 Novartis AG
6.3.1 Novartis AG Comapny Information
6.3.2 Novartis AG Business Overview
6.3.3 Novartis AG Biosimilar Therapeutic Peptides Revenue and Gross Margin (US$ Million) & (2020-2025)
6.3.4 Novartis AG Biosimilar Therapeutic Peptides Product Portfolio
6.3.5 Novartis AG Recent Developments
6.4 li Lilly and Company
6.4.1 li Lilly and Company Comapny Information
6.4.2 li Lilly and Company Business Overview
6.4.3 li Lilly and Company Biosimilar Therapeutic Peptides Revenue and Gross Margin (US$ Million) & (2020-2025)
6.4.4 li Lilly and Company Biosimilar Therapeutic Peptides Product Portfolio
6.4.5 li Lilly and Company Recent Developments
6.5 Pfizer
6.5.1 Pfizer Comapny Information
6.5.2 Pfizer Business Overview
6.5.3 Pfizer Biosimilar Therapeutic Peptides Revenue and Gross Margin (US$ Million) & (2020-2025)
6.5.4 Pfizer Biosimilar Therapeutic Peptides Product Portfolio
6.5.5 Pfizer Recent Developments
6.6 GlaxoSmithKline
6.6.1 GlaxoSmithKline Comapny Information
6.6.2 GlaxoSmithKline Business Overview
6.6.3 GlaxoSmithKline Biosimilar Therapeutic Peptides Revenue and Gross Margin (US$ Million) & (2020-2025)
6.6.4 GlaxoSmithKline Biosimilar Therapeutic Peptides Product Portfolio
6.6.5 GlaxoSmithKline Recent Developments
6.7 Amgen
6.7.1 Amgen Comapny Information
6.7.2 Amgen Business Overview
6.7.3 Amgen Biosimilar Therapeutic Peptides Revenue and Gross Margin (US$ Million) & (2020-2025)
6.7.4 Amgen Biosimilar Therapeutic Peptides Product Portfolio
6.7.5 Amgen Recent Developments
6.8 AstraZeneca
6.8.1 AstraZeneca Comapny Information
6.8.2 AstraZeneca Business Overview
6.8.3 AstraZeneca Biosimilar Therapeutic Peptides Revenue and Gross Margin (US$ Million) & (2020-2025)
6.8.4 AstraZeneca Biosimilar Therapeutic Peptides Product Portfolio
6.8.5 AstraZeneca Recent Developments
6.9 Teva Pharmaceuticals
6.9.1 Teva Pharmaceuticals Comapny Information
6.9.2 Teva Pharmaceuticals Business Overview
6.9.3 Teva Pharmaceuticals Biosimilar Therapeutic Peptides Revenue and Gross Margin (US$ Million) & (2020-2025)
6.9.4 Teva Pharmaceuticals Biosimilar Therapeutic Peptides Product Portfolio
6.9.5 Teva Pharmaceuticals Recent Developments
6.10 Novo Nordisk
6.10.1 Novo Nordisk Comapny Information
6.10.2 Novo Nordisk Business Overview
6.10.3 Novo Nordisk Biosimilar Therapeutic Peptides Revenue and Gross Margin (US$ Million) & (2020-2025)
6.10.4 Novo Nordisk Biosimilar Therapeutic Peptides Product Portfolio
6.10.5 Novo Nordisk Recent Developments
7 North America
7.1 North America Biosimilar Therapeutic Peptides Market Size (2020-2031)
7.2 North America Biosimilar Therapeutic Peptides Market Size by Type
7.2.1 North America Biosimilar Therapeutic Peptides Market Size by Type (2020-2025)
7.2.2 North America Biosimilar Therapeutic Peptides Market Size by Type (2026-2031)
7.2.3 North America Biosimilar Therapeutic Peptides Market Share by Type (2020-2031)
7.3 North America Biosimilar Therapeutic Peptides Market Size by Application
7.3.1 North America Biosimilar Therapeutic Peptides Market Size by Application (2020-2025)
7.3.2 North America Biosimilar Therapeutic Peptides Market Size by Application (2026-2031)
7.3.3 North America Biosimilar Therapeutic Peptides Market Share by Application (2020-2031)
7.4 North America Biosimilar Therapeutic Peptides Market Size by Country
7.4.1 North America Biosimilar Therapeutic Peptides Market Size by Country (2020 VS 2024 VS 2031)
7.4.2 North America Biosimilar Therapeutic Peptides Market Size by Country (2020-2025)
7.4.3 North America Biosimilar Therapeutic Peptides Market Size by Country (2026-2031)
7.4.4 North America Biosimilar Therapeutic Peptides Market Share by Country (2020-2031)
7.4.5 United States
7.4.6 Canada
7.4.7 Mexico
8 Europe
8.1 Europe Biosimilar Therapeutic Peptides Market Size (2020-2031)
8.2 Europe Biosimilar Therapeutic Peptides Market Size by Type
8.2.1 Europe Biosimilar Therapeutic Peptides Market Size by Type (2020-2025)
8.2.2 Europe Biosimilar Therapeutic Peptides Market Size by Type (2026-2031)
8.2.3 Europe Biosimilar Therapeutic Peptides Market Share by Type (2020-2031)
8.3 Europe Biosimilar Therapeutic Peptides Market Size by Application
8.3.1 Europe Biosimilar Therapeutic Peptides Market Size by Application (2020-2025)
8.3.2 Europe Biosimilar Therapeutic Peptides Market Size by Application (2026-2031)
8.3.3 Europe Biosimilar Therapeutic Peptides Market Share by Application (2020-2031)
8.4 Europe Biosimilar Therapeutic Peptides Market Size by Country
8.4.1 Europe Biosimilar Therapeutic Peptides Market Size by Country (2020 VS 2024 VS 2031)
8.4.2 Europe Biosimilar Therapeutic Peptides Market Size by Country (2020-2025)
8.4.3 Europe Biosimilar Therapeutic Peptides Market Size by Country (2026-2031)
8.4.4 Europe Biosimilar Therapeutic Peptides Market Share by Country (2020-2031)
8.4.5 Germany
8.4.6 France
8.4.7 U.K.
8.4.8 Italy
8.4.9 Russia
8.4.10 Nordic Countries
9 China
9.1 China Biosimilar Therapeutic Peptides Market Size (2020-2031)
9.2 China Biosimilar Therapeutic Peptides Market Size by Type
9.2.1 China Biosimilar Therapeutic Peptides Market Size by Type (2020-2025)
9.2.2 China Biosimilar Therapeutic Peptides Market Size by Type (2026-2031)
9.2.3 China Biosimilar Therapeutic Peptides Market Share by Type (2020-2031)
9.3 China Biosimilar Therapeutic Peptides Market Size by Application
9.3.1 China Biosimilar Therapeutic Peptides Market Size by Application (2020-2025)
9.3.2 China Biosimilar Therapeutic Peptides Market Size by Application (2026-2031)
9.3.3 China Biosimilar Therapeutic Peptides Market Share by Application (2020-2031)
10 Asia (Excluding China)
10.1 Asia Biosimilar Therapeutic Peptides Market Size (2020-2031)
10.2 Asia Biosimilar Therapeutic Peptides Market Size by Type
10.2.1 Asia Biosimilar Therapeutic Peptides Market Size by Type (2020-2025)
10.2.2 Asia Biosimilar Therapeutic Peptides Market Size by Type (2026-2031)
10.2.3 Asia Biosimilar Therapeutic Peptides Market Share by Type (2020-2031)
10.3 Asia Biosimilar Therapeutic Peptides Market Size by Application
10.3.1 Asia Biosimilar Therapeutic Peptides Market Size by Application (2020-2025)
10.3.2 Asia Biosimilar Therapeutic Peptides Market Size by Application (2026-2031)
10.3.3 Asia Biosimilar Therapeutic Peptides Market Share by Application (2020-2031)
10.4 Asia Biosimilar Therapeutic Peptides Market Size by Country
10.4.1 Asia Biosimilar Therapeutic Peptides Market Size by Country (2020 VS 2024 VS 2031)
10.4.2 Asia Biosimilar Therapeutic Peptides Market Size by Country (2020-2025)
10.4.3 Asia Biosimilar Therapeutic Peptides Market Size by Country (2026-2031)
10.4.4 Asia Biosimilar Therapeutic Peptides Market Share by Country (2020-2031)
10.4.5 Japan
10.4.6 South Korea
10.4.7 Taiwan
10.4.8 Southeast Asia
10.4.9 India
10.4.10 Australia
11 South America, Middle East & Africa
11.1 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Size (2020-2031)
11.2 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Type
11.2.1 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Type (2020-2025)
11.2.2 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Type (2026-2031)
11.2.3 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Share by Type (2020-2031)
11.3 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Application
11.3.1 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Application (2020-2025)
11.3.2 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Application (2026-2031)
11.3.3 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Share by Application (2020-2031)
11.4 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Country
11.4.1 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Country (2020 VS 2024 VS 2031)
11.4.2 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Country (2020-2025)
11.4.3 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Size by Country (2026-2031)
11.4.4 South America, Middle East & Africa Biosimilar Therapeutic Peptides Market Share by Country (2020-2031)
11.4.5 Brazil
11.4.6 South Africa
11.4.7 Saudi Arabia
11.4.8 Turkey
11.4.9 Argentina
11.4.9 UAE
11.4.9 Egypt
11.4.9 Chile
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
13.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.